

**Table 18: Clinical evidence profile: vitamin C versus allopurinol (in people not taking allopurinol at baseline)**

Certainty assessment							No of patients		Effect		Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Vitamin C supplement	allopurinol (people not taking allopurinol at baseline)	Relative (95% CI)	Absolute (95% CI)		

**Serum urate level (mmol/L) at 8 weeks (change score), better indicated by lower score**

1	randomised trials	very serious <sup>a</sup>	not serious	not serious	not serious	none	10	10	-	MD <b>0.15 higher</b> (0.08 higher to 0.22 higher)	⊕⊕○○ LOW	CRITICAL
---	-------------------	---------------------------	-------------	-------------	-------------	------	----	----	---	--	-------------	----------

a. Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias. For dichotomous outcomes MIDs were taken to be RRs of 0.8 and 1.25. For continuous outcomes 0.5 x baseline SD for continuous outcomes. Where there was only one study 0.5 (SMD) was used for continuous outcomes.